1
|
Aguilar-Ramírez E, Reyes-Pérez V, Fajardo-Hernández CA, Quezada-Suaste CD, Carreón-Escalante M, Merlin-Lucas V, Quiroz-García B, Granados-Soto V, Rivera-Chávez J. Harnessing the Reactivity of Duclauxin toward Obtaining hPTP1B 1-400 Inhibitors. J Med Chem 2023; 66:16222-16234. [PMID: 38051546 DOI: 10.1021/acs.jmedchem.3c01594] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2023]
Abstract
Duclauxin (1) from Talaromyces sp. IQ-313 was reported as a putative allosteric modulator of human recombinant protein tyrosine phosphatase 1B (400 amino acids) (hPTP1B1-400), a validated target for the treatment of type II diabetes. Based on these findings, a one-strain-many-compound (OSMAC) experiment on the IQ-313 strain generated derivatives 5a, 6, and 7. Moreover, a one-/two-step semisynthetic approach guided by docking toward hPTP1B1-400 produced 38 analogs, a series (A) incorporating a lactam functionalization at C-1 (8a-15a, 36a, and 37a) and a series (B) containing a lactam at C-1 and an extra unsaturation between C-7 and C-8 (5b, 11b-37b). In vitro evaluation and structure-activity relationship (SAR) analysis revealed that analogs from the B series are up to 10-fold more active than 1 and derivatives from the A series. Furthermore, duclauxin (1) and 36b were assessed for their potential acute toxicity, estimating their LD50 to be higher than 300 mg/kg. Moreover, 36b significantly reduced glycemia in an insulin tolerance test in mice, suggesting that its mechanism of action is through the PTP1B inhibition.
Collapse
Affiliation(s)
- Enrique Aguilar-Ramírez
- Department of Natural Products, Institute of Chemistry, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico
| | - Valeria Reyes-Pérez
- Department of Natural Products, Institute of Chemistry, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico
| | - Carlos A Fajardo-Hernández
- Department of Natural Products, Institute of Chemistry, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico
| | - Carlos D Quezada-Suaste
- Department of Natural Products, Institute of Chemistry, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico
| | - Mario Carreón-Escalante
- Department of Natural Products, Institute of Chemistry, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico
| | - Verenice Merlin-Lucas
- Department of Natural Products, Institute of Chemistry, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico
| | - Beatriz Quiroz-García
- Department of Natural Products, Institute of Chemistry, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico
| | - Vinicio Granados-Soto
- Pharmacobiology Department, Centro de Investigación y de Estudios Avanzados, Sede Sur, Mexico City 14330, Mexico
| | - José Rivera-Chávez
- Department of Natural Products, Institute of Chemistry, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico
| |
Collapse
|
2
|
Du L, Haldar S, King JB, Mattes AO, Srivastava S, Wendt KL, You J, Cunningham C, Cichewicz RH. Persephacin Is a Broad-Spectrum Antifungal Aureobasidin Metabolite That Overcomes Intrinsic Resistance in Aspergillus fumigatus. JOURNAL OF NATURAL PRODUCTS 2023; 86:1980-1993. [PMID: 37523665 DOI: 10.1021/acs.jnatprod.3c00382] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 08/02/2023]
Abstract
Fungi pose a persistent threat to humankind with worrying indications that emerging and re-emerging pathogens (e.g., Candida auris, Coccidioides spp., drug-resistant Aspergilli, and more) exhibit resistance to the limited number of approved antifungals. To address this problem, our team is exploring endophytic fungi as a resource for the discovery of new antifungal natural products. The rationale behind this decision is based on evidence that endophytes engage with plants in mutualistic relationships wherein some fungi actively participate by producing chemical defense measures that suppress pathogenic microorganisms. To improve the odds of bioactive metabolite discovery, we developed a new hands-free laser-cutting system capable of generating >50 plant samples per minute that, in turn, enabled our team to prepare and screen large numbers of endophytic fungi. One of the fungal isolates obtained in this way was identified as an Elsinoë sp. that produced a unique aureobasidin analogue, persephacin (1). Some distinctive features of 1 are the absence of both phenylalanine residues combined with the incorporation of a novel amino acid residue, persephanine (9). Compound 1 exhibits potent antifungal effects against a large number of pathogenic yeast (including several clinical C. auris strains), as well as phylogenetically diverse filamentous fungi (e.g., Aspergillus fumigatus). In an ex vivo eye infection model, compound 1 outperformed standard-of-care treatments demonstrating the ability to suppress fluconazole-resistant Candida albicans and A. fumigatus at a concentration (0.1% solution) well below the clinically recommended levels used for fluconazole and natamycin (2% and 5% solutions, respectively). In 3D tissue models for acute dermal and ocular safety, 1 was found to be nontoxic and nonirritating at concentrations required to elicit antifungal activity. Natural product 1 appears to be a promising candidate for further investigation as a broad-spectrum antifungal capable of controlling a range of pathogens that negatively impact human, animal, and plant health.
Collapse
Affiliation(s)
- Lin Du
- Natural Products Discovery Group, Institute for Natural Products Applications and Research Technologies, Department of Chemistry and Biochemistry, Stephenson Life Sciences Research Center, University of Oklahoma, Norman, Oklahoma 73019, United States
| | - Saikat Haldar
- Natural Products Discovery Group, Institute for Natural Products Applications and Research Technologies, Department of Chemistry and Biochemistry, Stephenson Life Sciences Research Center, University of Oklahoma, Norman, Oklahoma 73019, United States
| | - Jarrod B King
- Natural Products Discovery Group, Institute for Natural Products Applications and Research Technologies, Department of Chemistry and Biochemistry, Stephenson Life Sciences Research Center, University of Oklahoma, Norman, Oklahoma 73019, United States
| | - Allison O Mattes
- Natural Products Discovery Group, Institute for Natural Products Applications and Research Technologies, Department of Chemistry and Biochemistry, Stephenson Life Sciences Research Center, University of Oklahoma, Norman, Oklahoma 73019, United States
| | - Shikha Srivastava
- Natural Products Discovery Group, Institute for Natural Products Applications and Research Technologies, Department of Chemistry and Biochemistry, Stephenson Life Sciences Research Center, University of Oklahoma, Norman, Oklahoma 73019, United States
| | - Karen L Wendt
- Natural Products Discovery Group, Institute for Natural Products Applications and Research Technologies, Department of Chemistry and Biochemistry, Stephenson Life Sciences Research Center, University of Oklahoma, Norman, Oklahoma 73019, United States
| | - Jianlan You
- Natural Products Discovery Group, Institute for Natural Products Applications and Research Technologies, Department of Chemistry and Biochemistry, Stephenson Life Sciences Research Center, University of Oklahoma, Norman, Oklahoma 73019, United States
| | - Chad Cunningham
- Electronics & Instrument Shop, Department of Physics and Astronomy, Nielsen Hall, University of Oklahoma, Norman, Oklahoma 73019, United States
| | - Robert H Cichewicz
- Natural Products Discovery Group, Institute for Natural Products Applications and Research Technologies, Department of Chemistry and Biochemistry, Stephenson Life Sciences Research Center, University of Oklahoma, Norman, Oklahoma 73019, United States
| |
Collapse
|
3
|
Lander C, Satalkar V, Yang J, Pan X, Pei Z, Chatterji A, Liu C, Nicholas KM, Cichewicz RH, Yang Z, Shao Y. Visualization of Electron Density Changes Along Chemical Reaction Pathways. Mol Phys 2022; 121:e2113566. [PMID: 37638114 PMCID: PMC10448969 DOI: 10.1080/00268976.2022.2113566] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2022] [Accepted: 08/09/2022] [Indexed: 10/15/2022]
Abstract
We propose a simple procedure for visualizing the electron density changes (EDC) during a chemical reaction, which is based on a mapping of rectangular grid points for a stationary structure into (distorted) positions around atoms of another stationary structure. Specifically, during a small step along the minimum energy pathway (MEP), the displacement of each grid point is obtained as a linear combination of the motion of all atoms, with the contribution from each atom scaled by the corresponding Hirshfeld weight. For several reactions (identity SN2, Claisen rearrangement, Diels-Alder reaction, [3+2] cycloaddition, and phenylethyl mercaptan attack on pericosine A), our EDC plots showed an expected reduction of electron densities around severed bonds (or those with the bond-order lowered), with the opposite observed for newly-formed or enhanced chemical bonds. The EDC plots were also shown for copper triflate catalyzed N2O fragmentation, where the N-O bond weakening initially occurred on a singlet surface, but continued on a triplet surface after reaching the minimum-energy crossing point (MECP) between the two potential energy surfaces.
Collapse
Affiliation(s)
- Chance Lander
- Department of Chemistry and Biochemistry, University of Oklahoma, Norman, Oklahoma 73019, USAc)
| | - Vardhan Satalkar
- Department of Chemistry and Biochemistry, University of Oklahoma, Norman, Oklahoma 73019, USAc)
| | - Junjie Yang
- Department of Chemistry and Biochemistry, University of Oklahoma, Norman, Oklahoma 73019, USAc)
- School of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210046, China
- Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California 91125, USA
| | - Xiaoliang Pan
- Department of Chemistry and Biochemistry, University of Oklahoma, Norman, Oklahoma 73019, USAc)
| | - Zheng Pei
- Department of Chemistry and Biochemistry, University of Oklahoma, Norman, Oklahoma 73019, USAc)
| | - Aayushi Chatterji
- Department of Chemistry and Biochemistry, University of Oklahoma, Norman, Oklahoma 73019, USAc)
| | - Chungen Liu
- School of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210046, China
| | - Kenneth M. Nicholas
- Department of Chemistry and Biochemistry, University of Oklahoma, Norman, Oklahoma 73019, USAc)
| | - Robert H. Cichewicz
- Department of Chemistry and Biochemistry, University of Oklahoma, Norman, Oklahoma 73019, USAc)
| | - Zhibo Yang
- Department of Chemistry and Biochemistry, University of Oklahoma, Norman, Oklahoma 73019, USAc)
| | - Yihan Shao
- Department of Chemistry and Biochemistry, University of Oklahoma, Norman, Oklahoma 73019, USAc)
| |
Collapse
|
4
|
Usami Y, Nakamura K, Mizobuchi Y, Mizuki K, Harusawa S, Yoneyama H, Yamada T. Enantiomeric composition of natural pericosine A derived from Periconia byssoides and α-glycosidase inhibitory activity of (-)-enantiomer. Chirality 2022; 34:1320-1327. [PMID: 35775430 DOI: 10.1002/chir.23491] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2022] [Revised: 05/26/2022] [Accepted: 06/16/2022] [Indexed: 01/12/2023]
Abstract
Chiral high-performance liquid chromatography (HPLC) analysis of natural pericosine A, which appeared in literature first in 1977, from Periconia byssoides was conducted using a column CHIRALPAK® AD-H to determine the enantiomeric composition of the original mixture which was found to be 68: 32 mixtures of (+)- and (-)-enantiomer, respectively. Furthermore, two independently isolated samples of pericosine A from the same fungus were also analyzed to show the two peaks in the HPLC charts at approximate 1:1 ratio. These results concluded that pericosine A derived from Periconia byssoides was indeed an enantiomeric mixture. Synthesized enantiomers were subjected to evaluation of antitumor activity against three kinds of tumor cells (p388, L1210, HL-60), indicating moderate cytotoxicity against all three kinds of tumor cell lines, but significant difference in potency between the enantiomers was not observed. In contrast, when both the enantiomers of pericosine A were evaluated against five kinds of glycosidases-inhibitory activities (α- and β-glucosidases, α- and β-galactosidases, and α-mannosidase), an apparent difference on anti-glycosidase assay was found between the enantiomers: (-)-pericosine A inhibited α-glucosidase at IC50 : 2.25 mM, and β-galactosidase at IC50 : 5.38 mM, albeit the (+)-enantiomer showed inactivity against these five enzymes.
Collapse
Affiliation(s)
- Yoshihide Usami
- Department of Pharmaceutical Organic Chemistry, Osaka University of Pharmaceutical Sciences (Renamed as Osaka Medical and Pharmaceutical University in April 2021), Osaka, Japan
| | - Kimika Nakamura
- Department of Pharmaceutical Organic Chemistry, Osaka University of Pharmaceutical Sciences (Renamed as Osaka Medical and Pharmaceutical University in April 2021), Osaka, Japan
| | - Yoshino Mizobuchi
- Department of Pharmaceutical Organic Chemistry, Osaka University of Pharmaceutical Sciences (Renamed as Osaka Medical and Pharmaceutical University in April 2021), Osaka, Japan
| | - Koji Mizuki
- Department of Pharmaceutical Organic Chemistry, Osaka University of Pharmaceutical Sciences (Renamed as Osaka Medical and Pharmaceutical University in April 2021), Osaka, Japan
| | - Shinya Harusawa
- Department of Pharmaceutical Organic Chemistry, Osaka University of Pharmaceutical Sciences (Renamed as Osaka Medical and Pharmaceutical University in April 2021), Osaka, Japan
| | - Hiroki Yoneyama
- Department of Pharmaceutical Organic Chemistry, Osaka University of Pharmaceutical Sciences (Renamed as Osaka Medical and Pharmaceutical University in April 2021), Osaka, Japan
| | - Takeshi Yamada
- Department of Medicinal Molecular Chemistry, Osaka University of Pharmaceutical Sciences, Osaka, Japan
| |
Collapse
|
5
|
Usami Y, Mizobuchi Y, Ijuin M, Yamada T, Morita M, Mizuki K, Yoneyama H, Harusawa S. Synthesis of 6-Halo-Substituted Pericosine A and an Evaluation of Their Antitumor and Antiglycosidase Activities. Mar Drugs 2022; 20:md20070438. [PMID: 35877731 PMCID: PMC9323573 DOI: 10.3390/md20070438] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2022] [Revised: 06/25/2022] [Accepted: 06/28/2022] [Indexed: 11/16/2022] Open
Abstract
The enantiomers of 6-fluoro-, 6-bromo-, and 6-iodopericosine A were synthesized. An efficient synthesis of both enantiomers of pericoxide via 6-bromopericosine A was also developed. These 6-halo-substituted pericosine A derivatives were evaluated in terms of their antitumor activity against three types of tumor cells (p388, L1210, and HL-60) and glycosidase inhibitory activity. The bromo- and iodo-congeners exhibited moderate antitumor activity similar to pericosine A against the three types of tumor cell lines studied. The fluorinated compound was less active than the others, including pericosine A. In the antitumor assay, no significant difference in potency between the enantiomers was observed for any of the halogenated compounds. Meanwhile, the (−)-6-fluoro- and (−)-6-bromo-congeners inhibited α-glucosidase to a greater extent than those of their corresponding (+)-enantiomers, whereas (+)-iodopericosine A showed increased activity when compared to its (−)-enantiomer.
Collapse
Affiliation(s)
- Yoshihide Usami
- Department of Pharmaceutical Organic Chemistry, Osaka University of Pharmaceutical Sciences, Nasahara 4-20-1, Takatsuki 569-1094, Osaka, Japan; (Y.M.); (M.I.); (M.M.); (K.M.); (H.Y.); (S.H.)
- Correspondence: ; Tel.: +81-796-90-1087; Fax: +81-796-90-1005
| | - Yoshino Mizobuchi
- Department of Pharmaceutical Organic Chemistry, Osaka University of Pharmaceutical Sciences, Nasahara 4-20-1, Takatsuki 569-1094, Osaka, Japan; (Y.M.); (M.I.); (M.M.); (K.M.); (H.Y.); (S.H.)
| | - Mai Ijuin
- Department of Pharmaceutical Organic Chemistry, Osaka University of Pharmaceutical Sciences, Nasahara 4-20-1, Takatsuki 569-1094, Osaka, Japan; (Y.M.); (M.I.); (M.M.); (K.M.); (H.Y.); (S.H.)
| | - Takeshi Yamada
- Department of Medicinal Molecular Chemistry, Osaka University of Pharmaceutical Sciences, Nasahara 4-20-1, Takatsuki 569-1094, Osaka, Japan;
| | - Mizuki Morita
- Department of Pharmaceutical Organic Chemistry, Osaka University of Pharmaceutical Sciences, Nasahara 4-20-1, Takatsuki 569-1094, Osaka, Japan; (Y.M.); (M.I.); (M.M.); (K.M.); (H.Y.); (S.H.)
| | - Koji Mizuki
- Department of Pharmaceutical Organic Chemistry, Osaka University of Pharmaceutical Sciences, Nasahara 4-20-1, Takatsuki 569-1094, Osaka, Japan; (Y.M.); (M.I.); (M.M.); (K.M.); (H.Y.); (S.H.)
| | - Hiroki Yoneyama
- Department of Pharmaceutical Organic Chemistry, Osaka University of Pharmaceutical Sciences, Nasahara 4-20-1, Takatsuki 569-1094, Osaka, Japan; (Y.M.); (M.I.); (M.M.); (K.M.); (H.Y.); (S.H.)
| | - Shinya Harusawa
- Department of Pharmaceutical Organic Chemistry, Osaka University of Pharmaceutical Sciences, Nasahara 4-20-1, Takatsuki 569-1094, Osaka, Japan; (Y.M.); (M.I.); (M.M.); (K.M.); (H.Y.); (S.H.)
| |
Collapse
|